• No results found

University of Groningen Stapled peptides inhibitors Ali, Amina

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Stapled peptides inhibitors Ali, Amina"

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Stapled peptides inhibitors Ali, Amina

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Ali, A. (2019). Stapled peptides inhibitors: A new window for target drug discovery. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Propositions

Belonging to the thesis

Stapled Peptides Inhibitors: A new Window

For Target Drug Discovery

By

Amina M. Ali

1. Stapled peptides define a novel therapeutic modality & show an ability to inhibit intracellular PPIs that intractable with traditional small-molecule or protein-based therapeutics.{This thesis} 2. Stapled peptides fill the gap between small-molecules and biologics, opening an expansive

range of new therapeutic targets that were previously considered “undruggable”. {This thesis} 3. The large, shallow PPI interfaces were challenging to target, until the structural, screening,

synthetic chemistry and computational approaches have been evolved. {My view}

4. Our novel high-resolution structures will open ongoing endeavor to discover new p53-MDM2 PPI inhibitors to overcome the poor clinical and pharmacokinetic properties of the current once in clinical trials. {My view}

5. Great achievement always requires great sacrifices. {Robin Sharma} 6. It is always seems impossible until it’s done. {Nelson Mandela}

7. The greatest pleasure in life is doing what others say you cannot do. {Walter Bagehot}

8. Dream is not the thing you see in sleep,, but is that thing that doesn’t let you sleep. {A. P. J.

Abdul Kalam}

9. Mindset is what separates the best from the rest. {John Assaraf}

10. If you are always trying to be normal,, you will never know how amazing you can be. {Maya

Referenties

GERELATEERDE DOCUMENTEN

After the mtroduction of a new pasteunsed factor VIII concentrate (Factor VIIICPS-P) m The Netherlands rn June 1990, an mcrease m the occurrence of inhibitois m hemophihaA patients

From these four compounds, the esterified enantiomer (R)-5a was active in cells, which was evidenced by the increase of p53 levels, the induction of expression of p53-target

Refolding of proteins derived from inclusion bodies is very promising as it can provide a reliable source of target proteins of high purity. However, inclusion body-based

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright

“Screening for MDM2 Small Molecule Inhibitors: Cancer Therapeutic Target” • Pharmacy Day 2018, University of Groningen, (Oral presentation). “Screening for MDM2-p53 Inhibitors:

Matthew Groves, Assistance Professor in Drug Design Group- Groningen University, I am grateful for your tremendous support and for allowing me to grow as a research

Although structure-based models also performed worse for targets with less compound data and less crystal structures, this could partially be resolved by creation of additional

Studies with melanoma, NSCLC, renal cancer, SCCHN, and urothelial carcinoma found that intratumoral PD-L1 expression prior to treatment provides a higher likelihood for